|
Gene: RNASEH2C |
Gene summary for RNASEH2C |
Gene summary. |
Gene information | Species | Human | Gene symbol | RNASEH2C | Gene ID | 84153 |
Gene name | ribonuclease H2 subunit C | |
Gene Alias | AGS3 | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R5B3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84153 | RNASEH2C | P42T-E | Human | Esophagus | ESCC | 6.24e-18 | 6.46e-01 | 0.1175 |
84153 | RNASEH2C | P44T-E | Human | Esophagus | ESCC | 6.97e-16 | 4.28e-01 | 0.1096 |
84153 | RNASEH2C | P47T-E | Human | Esophagus | ESCC | 9.31e-15 | 2.47e-01 | 0.1067 |
84153 | RNASEH2C | P48T-E | Human | Esophagus | ESCC | 8.69e-21 | 1.44e-01 | 0.0959 |
84153 | RNASEH2C | P49T-E | Human | Esophagus | ESCC | 2.76e-23 | 2.33e+00 | 0.1768 |
84153 | RNASEH2C | P52T-E | Human | Esophagus | ESCC | 5.37e-38 | 7.29e-01 | 0.1555 |
84153 | RNASEH2C | P54T-E | Human | Esophagus | ESCC | 3.79e-12 | 1.68e-01 | 0.0975 |
84153 | RNASEH2C | P56T-E | Human | Esophagus | ESCC | 2.89e-06 | 7.10e-01 | 0.1613 |
84153 | RNASEH2C | P57T-E | Human | Esophagus | ESCC | 6.14e-17 | 3.66e-01 | 0.0926 |
84153 | RNASEH2C | P61T-E | Human | Esophagus | ESCC | 4.39e-19 | 4.23e-01 | 0.099 |
84153 | RNASEH2C | P62T-E | Human | Esophagus | ESCC | 3.12e-35 | 7.18e-01 | 0.1302 |
84153 | RNASEH2C | P65T-E | Human | Esophagus | ESCC | 4.83e-16 | 2.44e-01 | 0.0978 |
84153 | RNASEH2C | P74T-E | Human | Esophagus | ESCC | 8.77e-48 | 1.52e+00 | 0.1479 |
84153 | RNASEH2C | P75T-E | Human | Esophagus | ESCC | 8.41e-46 | 9.06e-01 | 0.1125 |
84153 | RNASEH2C | P76T-E | Human | Esophagus | ESCC | 4.35e-20 | 5.96e-01 | 0.1207 |
84153 | RNASEH2C | P79T-E | Human | Esophagus | ESCC | 3.82e-29 | 7.13e-01 | 0.1154 |
84153 | RNASEH2C | P80T-E | Human | Esophagus | ESCC | 4.10e-41 | 1.14e+00 | 0.155 |
84153 | RNASEH2C | P82T-E | Human | Esophagus | ESCC | 5.50e-18 | 1.12e+00 | 0.1072 |
84153 | RNASEH2C | P83T-E | Human | Esophagus | ESCC | 6.23e-15 | 3.58e-01 | 0.1738 |
84153 | RNASEH2C | P89T-E | Human | Esophagus | ESCC | 1.49e-19 | 1.44e+00 | 0.1752 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000640113 | Breast | IDC | RNA catabolic process | 38/1434 | 278/18723 | 3.54e-04 | 5.16e-03 | 38 |
GO:190136112 | Breast | IDC | organic cyclic compound catabolic process | 56/1434 | 495/18723 | 2.12e-03 | 1.99e-02 | 56 |
GO:004670012 | Breast | IDC | heterocycle catabolic process | 51/1434 | 445/18723 | 2.51e-03 | 2.25e-02 | 51 |
GO:003465513 | Breast | IDC | nucleobase-containing compound catabolic process | 47/1434 | 407/18723 | 3.12e-03 | 2.63e-02 | 47 |
GO:004427012 | Breast | IDC | cellular nitrogen compound catabolic process | 50/1434 | 451/18723 | 5.29e-03 | 3.93e-02 | 50 |
GO:001943912 | Breast | IDC | aromatic compound catabolic process | 51/1434 | 467/18723 | 6.54e-03 | 4.59e-02 | 51 |
GO:000640123 | Breast | DCIS | RNA catabolic process | 38/1390 | 278/18723 | 1.91e-04 | 3.08e-03 | 38 |
GO:003465522 | Breast | DCIS | nucleobase-containing compound catabolic process | 47/1390 | 407/18723 | 1.69e-03 | 1.68e-02 | 47 |
GO:190136122 | Breast | DCIS | organic cyclic compound catabolic process | 55/1390 | 495/18723 | 1.75e-03 | 1.71e-02 | 55 |
GO:004670022 | Breast | DCIS | heterocycle catabolic process | 50/1390 | 445/18723 | 2.19e-03 | 2.03e-02 | 50 |
GO:001943922 | Breast | DCIS | aromatic compound catabolic process | 51/1390 | 467/18723 | 3.58e-03 | 2.92e-02 | 51 |
GO:004427022 | Breast | DCIS | cellular nitrogen compound catabolic process | 49/1390 | 451/18723 | 4.68e-03 | 3.56e-02 | 49 |
GO:000640120 | Esophagus | HGIN | RNA catabolic process | 77/2587 | 278/18723 | 7.63e-10 | 6.36e-08 | 77 |
GO:003465519 | Esophagus | HGIN | nucleobase-containing compound catabolic process | 98/2587 | 407/18723 | 1.44e-08 | 8.94e-07 | 98 |
GO:004670017 | Esophagus | HGIN | heterocycle catabolic process | 103/2587 | 445/18723 | 5.44e-08 | 2.99e-06 | 103 |
GO:004427018 | Esophagus | HGIN | cellular nitrogen compound catabolic process | 103/2587 | 451/18723 | 1.10e-07 | 5.56e-06 | 103 |
GO:001943917 | Esophagus | HGIN | aromatic compound catabolic process | 105/2587 | 467/18723 | 1.89e-07 | 9.31e-06 | 105 |
GO:190136117 | Esophagus | HGIN | organic cyclic compound catabolic process | 106/2587 | 495/18723 | 1.94e-06 | 7.13e-05 | 106 |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030304 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
hsa0303011 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
hsa03030 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
hsa030301 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
hsa030302 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
hsa030303 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNASEH2C | SNV | Missense_Mutation | novel | c.364N>A | p.Ala122Thr | p.A122T | Q8TDP1 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
RNASEH2C | SNV | Missense_Mutation | c.115N>C | p.Asp39His | p.D39H | Q8TDP1 | protein_coding | deleterious(0.01) | benign(0.315) | TCGA-DD-A1EL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
RNASEH2C | SNV | Missense_Mutation | c.191N>A | p.Arg64Gln | p.R64Q | Q8TDP1 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-BR-8363-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RNASEH2C | SNV | Missense_Mutation | novel | c.360N>G | p.Ile120Met | p.I120M | Q8TDP1 | protein_coding | tolerated(0.27) | benign(0.018) | TCGA-CG-4438-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |